A Study of ERY974 in Patient With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chugai Pharmaceutical

Criteria

Inclusion Criteria:

• Male or female patient with Glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated

• Measurable tumor

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

• Adequate bone marrow, liver, and renal function

• Adequate coagulation status

Exclusion Criteria:

• Patients with more than a single brain metastasis ( >1 cm)

• Patients with acute or chronic infection

• Major surgery within 28 days

• Pregnant or lactating women

• Patients with interstitial pneumonitis

• Patients require regular ascites/pleural effusion drainage